The Ohio State University

Pharmacyclics, Inc.

Novartis Ag

University of Pennsylvania

Immunomedics, Inc.

Natarajan Muthusamy

John C Byrd

Amy Jo Johnson

Jason A Dubovsky

Ching-Shih Chen

David Miklos

Danilo Perrotti

David M Goldenberg

Hans J Hansen

Carl H June

James T Dalton

Tarak D Mody

Joseph J Buggy

Jennifer Brogdon

Saar Gill

David Jonathan Glass

Marcela V Maus

Joan Mannick

Leon Murphy

David L Porter

Anna Vulpetti

Marco Ruella

Dasheng Wang

Samuel K Kulp

Guido Marcucci

Mariusz Wasik

Daniela Angst

Saad Kenderian

Robert A Baiocchi

William Raj Sellers

Betty Chang

Paolo Neviani

Joseph Fraietta

Ramasamy Santhanam

Lapo Alinari

Frank Frissora

Xiaobin Zhao

Qing Liu

Joseph A Fraietta

Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease.

Methods of treating and preventing graft versus host disease

The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.

Treatment of cancer using anti-CD19 Chimeric Antigen Receptor

Described herein are methods and compositions comprising a covalent TEC family kinase inhibitor for use in adjuvant therapy, including adjuvant cancer therapy, vaccination and treatment of immune disorders and pathogenic infections.

TEC family kinase inhibitor adjuvant therapy

The invention provides for methods of treating a mammal who has a BCR/ABL-mediated leukemia, including chronic myelogenous leukemia (CML), particularly the blast crisis stage of CML, Philadelphia-positive acute lymphoblastic leukemia (Ph'-ALL), and refractory leukemias. The invention also provides for compounds for the treatment of these leukemias and methods of identifying anti-leukemic agents.

Therapeutic agents for the treatment of leukemia

Disclosed herein are methods and compositions comprising fingolimod and anti-CD74 antibodies or fragments thereof. In preferred embodiments, the fingolimod increases the expression of CD74 in target cells and increases the sensitivity of the cells to the cytotoxic effects of the anti-CD74 antibodies. The compositions and methods are of use to treat diseases involving CD74cells, such as cancer cells, autoimmune disease cells or immune dysfunction disease cells.

FTY720 increases CD74 expression and sensitizes cancer cells to anti-CD74 antibody-mediated cell death

Methods&#x2014;for treatment and prevention of lymphoid malignancies, including, but not limited to acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell lymphoma, Acute Myeloid leukemia (AML), and mantle cell lymphoma (MCL). The methods include administration of a therapeutically effective amount of FTY720 (2-Amino-2-[2-(4-octylphenyl)ethyl]propane 1,3-diol hydrochloride) or a derivative, pharmaceutically acceptable salt thereof, or a prodrug thereof to a subject.

Therapeutic agents for the treatment of lymphoid malignancies

A number of FTY720-derived compounds with antitumor activity are described. These compounds include the compounds of formula I: wherein Ris independently selected from the group consisting of hydrogen, methyl. methoxy, and hydroxyl; Ris independently selected from the group consisting of hydrogen, methoxy, and hydroxyl; Ris independently selected from the group consisting of alkyl and cyclo-alkyl; and n is independently selected from 0 to 6. The compounds have lower immunosuppressive side effects as a result of not being phosphorylated by sphingosine kinase 2.

FTY720-derived anticancer agents

Growing community of inventors

Galloway, OH, United States of America

Natarajan Muthusamy